Goldman Sachs’s ARK Genomic Revolution ETF ARKG Stock Holding History

Goldman Sachs’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50,000	Closed	-$1.41M	–	5901
2022 Q4	$1.41M	Hold	50,000	–	–	﹤0.01%	4191
2022 Q3	$1.64M	Sell	50,000 -35,000	-41%	-$1.28M	﹤0.01%	4139
2022 Q2	$2.68M	Sell	85,000 -367,900	-81%	-$12.9M	﹤0.01%	3784
2022 Q1	$20.8M	Buy	452,900 +90,800	+25%	+$4.33M	﹤0.01%	2017
2021 Q4	$22.2M	Buy	362,100 +312,100	+624%	+$21.6M	﹤0.01%	2026
2021 Q3	$3.74M	Sell	50,000 -386,400	-89%	-$32.4M	﹤0.01%	3603
2021 Q2	$40.4M	Buy	+436,400	New	+$37.1M	0.01%	1444

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs's ARKG Position: Q2 2026 in Review

Goldman Sachs increased its ARK Genomic Revolution ETF (ARKG) stake by 5.6% in Q2 2026, buying an estimated $5.08M and bringing the position to 3,016,963 shares worth $127M. The position accounts for 0.01% of the portfolio, ranked #1054.

Goldman Sachs first reported a position in ARKG in Q4 2020 and has held it in 23 quarters since. 272 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Goldman Sachs held 3,016,963 shares of ARK Genomic Revolution ETF worth $127M as of Q2 2026.
Goldman Sachs bought 159,569 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $5.08M.
ARK Genomic Revolution ETF made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1054 holding.
Goldman Sachs first reported a position in ARK Genomic Revolution ETF in Q4 2020 and has held it in 23 quarters since.
272 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.